Authors
Latest:
Dr Shen on the Utility of ARX517 in mCRPCJohn Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple MyelomaYago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Latest:
Dr King on the Need for Less-Toxic Therapies in Advanced Gastrointestinal CancersDaniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.
Latest:
Dr. Wang on Challenges With Checkpoint Inhibitors in CRCTimothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.
Latest:
Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell LymphomasHemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.
Latest:
Women in Oncology: Prioritization and Passionate LegaciesSelina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Latest:
Dr Lobbous on Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer Leptomeningeal MetastasesMina Lobbous, MD, MPH, on tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases from HER2-positive breast cancer.
Latest:
Dr Cun on Molecular Classification in Endometrioid Endometrial AdenocarcinomaHan T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.
Latest:
Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast CancerNina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
Latest:
Palliative Care Can Address Gaps in Oncology LandscapePalliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.
Latest:
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLLAt the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
Latest:
Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNALu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.
Latest:
Dr. Ratan on the Steps of Diagnosing Desmoid TumorsRavin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.
Latest:
Dr Haffty on Radiation in Node-Positive Breast Cancer That Converts to Node NegativeBruce G. Haffty, MD, MS, FACR, FASTRO, discusses the use of radiation in node-positive breast cancer patients who convert to node-negative status after neoadjuvant chemotherapy.
Latest:
Immune Checkpoint Inhibitors Extend Survival for MesotheliomaImmune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.
Latest:
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML ConsortiumA Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.
Latest:
Dr Garje on the Benefits of Multimodal Treatment in Small Cell Bladder CancerRohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Dr Takvorian on the Evolution of PARP Inhibitors in Prostate CancerSamuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.
Latest:
Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic CancerReema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.
Latest:
Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCLJoseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
Latest:
Dr Semaan on Liquid Biopsy vs Tissue Biopsy for Detecting Sarcomatoid RCCKarl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.
Latest:
EGFR+ NSCLC: Advice for Community OncologistsA panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Latest:
Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.
Latest:
Monitoring and Follow-Up of Patients with Chronic GVHDThe panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.
Latest:
Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric CancerWarren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.
Latest:
Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in HematologyCiara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.
Latest:
Discovering New Medicines in CancerOur ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.
Latest:
Clinical Pearls and Impacts to Practice from EHA 2024The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.
.jpg?fit=crop&auto=format)
